Physician profile
Wesley Ward
NPI 1881170611
$1,531.96
in general payments reported to CMS, 2019-2025
15 companies · $934 in 2025
The $934 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $89.08 · 2023: $182 · 2024: $327 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,371 · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,371.39 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $536.70 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $268.50 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $152.75 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $101.05 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $89.97 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $76.39 | 2022-2025 | Invega Sustenna |
| Alkermes, INC. | $75.76 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.26 | 2025 | Caplyta |
| Novo Nordisk INC | $45.33 | 2022-2025 | Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $44.39 | 2024 | Auvelity |
| Neurocrine Biosciences, INC. | $20.47 | 2025 | |
| Exact Sciences Corporation | $20.43 | 2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $19.87 | 2024 | Qelbree |
| Genentech USA, INC. | $17.54 | 2022 | |
| Lundbeck LLC | $16.55 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.